Healthcare services company Curative Insurance Company and GRAIL, a healthcare company whose mission is to detect cancer early when it can be cured, announced the availability of Galleri, a multi-cancer early detection (MCED) screening test to eligible insurance plan members.
The Galleri test will be available to all members, across all plan types, who are over the age of 50 and to all other members with risk factors for developing cancer. The Galleri test is part of the list of benefit offerings available for $0 copay and $0 deductible* on Curative’s health insurance plan.
A simple blood draw used in addition to current single-cancer screenings, Galleri can identify DNA shed by cancer cells to help screen for some of the deadliest cancers that don’t have recommended screening today, such as pancreatic, esophageal, ovarian, liver, and others, according to the company. Studies have shown a 75% sensitivity for screening cancers responsible for two-thirds of cancer deaths, rising as high as 80% for the most serious cancers. Galleri can indicate the origin of the cancer with 88% accuracy, giving doctors a roadmap for where to explore further.